Kidney Cancer Association | Association Partnerships

November 18, 2021

In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.

November 08, 2021

Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.

November 07, 2021

Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.

November 07, 2021

New findings suggest that understanding subtypes of non-clear cell renal cell carcinoma is important for personalizing treatment.

November 06, 2021

James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.

November 06, 2021

The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.